Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.05 · Revenue $0.00 · 1 analysts
Est. EPS $-0.05 · Revenue $0.00 · 1 analysts
Est. EPS $-0.30 · Revenue $179.69M · 1 analysts
Est. EPS $-0.23 · Revenue $385.24M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-30.8M | +34.5% | -80.6% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-23.9M | +42.8% | +36.9% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | -106.0% | -2.8% | +3.4% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 2.42x | +396.8% | -95.5% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $19.5M | +11.6% | -5.9% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.48 vs -0.49 | +2.0% | -0.14 vs -0.09 | -55.6% |
| Revenue Surprise | $0 vs $36.3M | -100.0% | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jul 31, 2026 | Uihlein Richard E | director, 10 percent owner: | Common Stock | A | 2,550,932 | $4.05 |
| Jul 31, 2026 | Uihlein Richard E | director, 10 percent owner: | Common Stock | A | 31,825,235 | $3.00 |
| Jul 31, 2026 | Uihlein Richard E | director, 10 percent owner: | Line of Credit Convertible Notes | D | 0 | $4.05 |
| Jul 31, 2026 | Uihlein Richard E | director, 10 percent owner: | Line of Credit Convertible Notes | D | 0 | $3.00 |
| Jul 14, 2026 | Jamil Khurram | officer: Chief Medical Officer | Stock option (right to buy) | D | 16,250 | $3.04 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Joel Lewis | President & CEO | USD 992,019 | Male | 1970 | Active |
Khurram Jamil | Chief Medical Officer | USD 921,583 | Male | 1976 | Active |
Jack W. Callicutt | Chief Financial Officer, Treasurer & Corporate Secretary | USD 676,019 | Male | 1967 | Active |
Jim Wilkins | Head of CMC & Pharmaceutical Development | — | Male | — | Active |
Beth Knowles | Executive Assistant & Officer Manager | — | Female | — | Active |
Robert Tritt | General Counsel | — | Male | — | Active |
NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2026.
Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock Transaction eliminates approximately $105.8 million in debt and increases market capitalization NORCROSS, Ga.
Galectin Therapeutics remains a buy as recent FDA alignment de-risks belapectin's Phase 3 path and clarifies regulatory endpoints. The FDA's endorsement of a single, well-controlled Phase 3 trial with a composite clinical outcome endpoint reduces uncertainty and shortens timelines. GALT's valuation reflects skepticism about execution, financing risk, and commercial viability, but successful Phase 3 results could trigger a significant re-rating.
Galectin stock rises following FDA alignment on key elements of belapectin's phase III MASH cirrhosis program, clarifying a potential path toward full approval.
NORCROSS, Ga., June 23, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), a biotechnology company focused on developing therapies for patients with advanced liver disease, today announced positive feedback from its recent in person Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of belapectin for the treatment of patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension.
